She was pregnant with her first child when a midwife appointment took an unexpected turn.

On the FDA’s docket for the back half of September is Merck’s proposed subcutaneous formulation of its blockbuster cancer drug Keytruda.

With the global rise of a “Parkinson’s Pandemic,” researchers have high hopes that prescribing exercise can slow the ...